TY - JOUR

T1 - New Clinical Phenotype of the Post-Covid Syndrome

T2 - Fibromyalgia and Joint Hypermobility Condition

AU - Gavrilova, Natalia

AU - Soprun, Lidiia

AU - Lukashenko, Maria

AU - Ryabkova, Varvara

AU - Fedotkina, Tamara V.

AU - Churilov, Leonid P.

AU - Shoenfeld, Yehuda

N1 - Gavrilova, N.; Soprun, L.; Lukashenko, M.; Ryabkova, V.; Fedotkina, T.V.; Churilov, L.P.; Shoenfeld, Y. New Clinical Phenotype of the Post-Covid Syndrome: Fibromyalgia and Joint Hypermobility Condition. Pathophysiology 2022, 29, 24-29. https://doi.org/10.3390/pathophysiology29010003

PY - 2022/1/19

Y1 - 2022/1/19

N2 - Fibromyalgia can be defined as a chronic pain condition, affecting the musculoskeletal sys-tem, etiology and pathophysiology of which is sufficiently understudied. Despite the fact that many authors consider this entity to be a manifestation of central sensitization, and not an autoimmune dis-ease, the high prevalence of fibromyalgia in patients with post-COVID-19 conditions requires taking a fresh look at the causes of the disease development. During the patient examination, the authors identified a combination of symptoms that occurs so often, that they can be carefully described as a clinical pattern. These manifestations include young age, female gender, joint hypermobility, the onset of pain after COVID-19, physical traumatization of one particular tendon and the development of the fibromyalgia pain syndrome during the next several weeks. As well as an increase in the titer of antinuclear antibodies and some other systemic inflammation factors. It can be assumed with great caution that local damage to the connective tissue in patients with joint hypermobility, having COVID-19 as a trigger factor can lead to the development of fibromyalgia syndrome. This article presents three clinical cases that illustrated this hypothesis.

AB - Fibromyalgia can be defined as a chronic pain condition, affecting the musculoskeletal sys-tem, etiology and pathophysiology of which is sufficiently understudied. Despite the fact that many authors consider this entity to be a manifestation of central sensitization, and not an autoimmune dis-ease, the high prevalence of fibromyalgia in patients with post-COVID-19 conditions requires taking a fresh look at the causes of the disease development. During the patient examination, the authors identified a combination of symptoms that occurs so often, that they can be carefully described as a clinical pattern. These manifestations include young age, female gender, joint hypermobility, the onset of pain after COVID-19, physical traumatization of one particular tendon and the development of the fibromyalgia pain syndrome during the next several weeks. As well as an increase in the titer of antinuclear antibodies and some other systemic inflammation factors. It can be assumed with great caution that local damage to the connective tissue in patients with joint hypermobility, having COVID-19 as a trigger factor can lead to the development of fibromyalgia syndrome. This article presents three clinical cases that illustrated this hypothesis.

KW - Autoimmunity

KW - Chronic fatigue syndrome

KW - Coronavirus infection

KW - Fibromyalgia

KW - Joint hypermobility

KW - Musculoskeletal disorders

KW - Pain syndrome

KW - Post-COVID-19 condition

UR - http://www.scopus.com/inward/record.url?scp=85123073689&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/86c19170-65c6-38d4-bfda-c1cb96ee11f8/

U2 - 10.3390/pathophysiology29010003

DO - 10.3390/pathophysiology29010003

M3 - Article

AN - SCOPUS:85123073689

VL - 29

SP - 24

EP - 29

JO - Pathophysiology

JF - Pathophysiology

SN - 0928-4680

IS - 1

ER -